Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer

• Main Authors: Jagadeeshan, Sankar, Prasad, Manu, Badarni, Mai, Ben-Lulu, Talal, Liju, Vijayasteltar Belsamma, Mathukkada, Sooraj, Saunders, Claire, Shnerb, Avital Beeri, Zorea, Jonathan, Yegodayev, Ksenia M., Wainer, Monica, Vtorov, Liza, Allon, Irit, Cohen, Ofir, Gausdal, Gro, Friedmann-Morvinski, Dinorah, Cheong, Sok Ching, Ho, Alan L., Rosenberg, Ari J., Kessler, Linda, Burrows, Francis, Kong, Dexin, Grandis, Jennifer R., Gutkind, J. Silvio, Elkabets, Moshe
• Format: Article
• Published: American Association for Cancer Research Inc. 2023
• Subjects: RC Internal medicine; RD Surgery
• Online Access: http://eprints.um.edu.my/38340/

The survival rate for patients with head and neck cancer (HNC) diagnosed with cervical lymph node (cLN) or distant metastasis is low. Genomic alterations in the HRAS oncogene are associated with advanced tumor stage and metastasis in HNC. Elucidation of the molecular mechanisms by which mutated HRAS...